WO1995001793A3 - 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain - Google Patents

5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain Download PDF

Info

Publication number
WO1995001793A3
WO1995001793A3 PCT/US1994/007488 US9407488W WO9501793A3 WO 1995001793 A3 WO1995001793 A3 WO 1995001793A3 US 9407488 W US9407488 W US 9407488W WO 9501793 A3 WO9501793 A3 WO 9501793A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
pain
treatment
disorders associated
peripheral disorders
Prior art date
Application number
PCT/US1994/007488
Other languages
French (fr)
Other versions
WO1995001793A2 (en
Inventor
Philippe Danjou
Original Assignee
American Home Prod
Philippe Danjou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod, Philippe Danjou filed Critical American Home Prod
Priority to AU72544/94A priority Critical patent/AU7254494A/en
Publication of WO1995001793A2 publication Critical patent/WO1995001793A2/en
Publication of WO1995001793A3 publication Critical patent/WO1995001793A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Abstract

Known 5-HT3 antagonists of specified formulae, e.g. (endo)-N-[[8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]carbonyl]-2-(cyclopropylmethoxy)benzamide or (endo)-1-cyclohexyl-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-4(1H)oxo-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof, are administered topically for the treatment of peripheral disorders associated with pain.
PCT/US1994/007488 1993-07-08 1994-07-06 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain WO1995001793A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU72544/94A AU7254494A (en) 1993-07-08 1994-07-06 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9314174.5 1993-07-08
GB939314174A GB9314174D0 (en) 1993-07-08 1993-07-08 5-ht3-antagonists

Publications (2)

Publication Number Publication Date
WO1995001793A2 WO1995001793A2 (en) 1995-01-19
WO1995001793A3 true WO1995001793A3 (en) 1995-03-30

Family

ID=10738511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/007488 WO1995001793A2 (en) 1993-07-08 1994-07-06 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain

Country Status (3)

Country Link
AU (1) AU7254494A (en)
GB (1) GB9314174D0 (en)
WO (1) WO1995001793A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537245A (en) 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト Use of 5-HT3 receptor antagonist
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323077A1 (en) * 1987-12-24 1989-07-05 JOHN WYETH & BROTHER LIMITED Heterocyclic compounds
EP0422846A2 (en) * 1989-10-07 1991-04-17 JOHN WYETH & BROTHER LIMITED Aroyl-ureas
WO1991005783A1 (en) * 1989-10-14 1991-05-02 John Wyeth & Brother Limited Heterocyclic compounds
EP0450345A1 (en) * 1990-03-24 1991-10-09 MERCK PATENT GmbH Indole derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323077A1 (en) * 1987-12-24 1989-07-05 JOHN WYETH & BROTHER LIMITED Heterocyclic compounds
EP0422846A2 (en) * 1989-10-07 1991-04-17 JOHN WYETH & BROTHER LIMITED Aroyl-ureas
WO1991005783A1 (en) * 1989-10-14 1991-05-02 John Wyeth & Brother Limited Heterocyclic compounds
EP0450345A1 (en) * 1990-03-24 1991-10-09 MERCK PATENT GmbH Indole derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J.GIORDANO ET AL.: "Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats", EUR.J.PHARMACOL., vol. 170, 1989, pages 83 - 86 *
K.F.RHODES ET AL.: "WAY 100289: Pharmacological Profile of a Novel 5-HT3 Receptor Antagonist", DRUG DEV. RES., vol. 28, no. 2, February 1993 (1993-02-01), pages 128 - 140 *
T.J.WARD: "WAY 100289", DRUGS FUTURE, vol. 18, no. 1, 1993, pages 23 - 24 *

Also Published As

Publication number Publication date
GB9314174D0 (en) 1993-08-18
WO1995001793A2 (en) 1995-01-19
AU7254494A (en) 1995-02-06

Similar Documents

Publication Publication Date Title
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
CA2235375A1 (en) Production of analgesic synergy by co-administration of sub-analgesic doses of a .mu. opioid agonist and a .kappa.-2 opioid agonist
CA2143864A1 (en) Morphinan derivatives and pharmaceutical use thereof
NO306457B1 (en) 2,4-disulfonylphenylbutylnitron, salts thereof, pharmaceutical composition, and the use of this compound in the manufacture of a medicament
CA2226934A1 (en) Ipratropium bromide enantiomer with a prolonged duration of action
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
YU49215B (en) The use of flupirtine to prepare a medicament for the treatment of neurodegenerative diseases
TW324662B (en) Benzamide-containing pharmaceutical composition
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
RU94002133A (en) 6-CHLOR-5-FTOR-3- (2-TENOIL) -2-OXINDOL-1-CARBOXAMIDE AS AN ANALOGESIC AND ANIMATERATIVE MEDICATION
WO1995001793A3 (en) 5-ht-3-antagonists as topical medicaments for treatment of peripheral disorders associated with pain
PL312198A1 (en) Application of procaine in obtaining a pharmaceutical preparation of analgesic activity with minimum motorial blocking effect
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
CA2128312A1 (en) Use of n-(pyridinyl)-1h-indol-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
AU634584B2 (en) Aroyl-ureas
GR3004113T3 (en)
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
EP0676206A4 (en)
IE872218L (en) Nicotinamide derivative as a therapeutic agent
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
MX9801222A (en) Composition containing mefenamic acid in association with codeine.
IT1251993B (en) Pharmaceutical compositions for oral use based on internal ganglioside esters for the treatment of neural diseases of the peripheral nervous system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AU BB BG BR BY CA CN CZ FI GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 446773

Date of ref document: 19950531

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA